Multimodal Assay Platforms for Understanding Alzheimer’s Disease Across Experimental and Translational Scales

Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by amyloid-β accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and progressive cognitive decline. Despite advances in experimental modeling and biomarker development, no single model or assay captures the biological complexity, age-related features, systemic influences, and clinical heterogeneity of human AD. This review critically evaluates multimodal assay platforms for investigating AD pathogenesis and therapeutic responses across experimental and translational scales. We define multimodal assay platforms as coordinated designs integrating three functionally linked components: (i) disease models in which defined biological processes can be observed or perturbed; (ii) experimental and clinical assays that generate complementary molecular, cellular, functional, imaging, and biofluid readouts; and (iii) human-reference datasets, biomarker-classification frameworks, and computational approaches that benchmark and interpret these readouts in relation to human AD. Multimodality therefore assigns each component a distinct inferential role-mechanistic discovery, causal interrogation, orthogonal validation, or translational anchoring, rather than simply accumulating techniques. We provide a question-driven roadmap linking biological questions to complementary model combinations and readouts while benchmarking their translational relevance against human-reference data. We discuss conventional in vitro models, emerging three-dimensional platforms, and genetic, induced, and humanized chimeric animal models. Finally, we examine how high-throughput screening, biofluid biomarkers, neuroimaging, amyloid/tau/neurodegeneration (AT(N))-based classification, multi-omics, and artificial intelligence (AI)-assisted computational approaches complement experimental platforms. Collectively, these platforms provide a tiered translational roadmap for model selection, mechanistic interpretation, and biomarker-informed therapeutic development.

Authors

Institutions

Publication Details

Journal
Cellular and Molecular Neurobiology
Published
2026-11-18
DOI
https://doi.org/10.1007/s10571-026-01865-w
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multimodal Assay Platforms for Understanding Alzheimer’s Disease Across Experimental and Translational Scales

Hyowon Hong, Hye Suk Baek, Shin Kim, SoHyeon Cheon et al.
2 links
Cellular and Molecular Neurobiology
Alzheimer's disease research and treatments
article

Multimodal Assay Platforms for Understanding Alzheimer’s Disease Across Experimental and Translational Scales

Hyowon Hong, Hye Suk Baek, Shin Kim, SoHyeon Cheon, Gahyeon Kim
article en

Abstract

Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by amyloid-β accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and progressive cognitive decline. Despite advances in experimental modeling and biomarker development, no single model or assay captures the biological complexity, age-related features, systemic influences, and clinical heterogeneity of human AD. This review critically evaluates multimodal assay platforms for investigating AD pathogenesis and therapeutic responses across experimental and translational scales. We define multimodal assay platforms as coordinated designs integrating three functionally linked components: (i) disease models in which defined biological processes can be observed or perturbed; (ii) experimental and clinical assays that generate complementary molecular, cellular, functional, imaging, and biofluid readouts; and (iii) human-reference datasets, biomarker-classification frameworks, and computational approaches that benchmark and interpret these readouts in relation to human AD. Multimodality therefore assigns each component a distinct inferential role-mechanistic discovery, causal interrogation, orthogonal validation, or translational anchoring, rather than simply accumulating techniques. We provide a question-driven roadmap linking biological questions to complementary model combinations and readouts while benchmarking their translational relevance against human-reference data. We discuss conventional in vitro models, emerging three-dimensional platforms, and genetic, induced, and humanized chimeric animal models. Finally, we examine how high-throughput screening, biofluid biomarkers, neuroimaging, amyloid/tau/neurodegeneration (AT(N))-based classification, multi-omics, and artificial intelligence (AI)-assisted computational approaches complement experimental platforms. Collectively, these platforms provide a tiered translational roadmap for model selection, mechanistic interpretation, and biomarker-informed therapeutic development.

Cellular and Molecular Neurobiology
Keimyung University (KR)
National Research Foundation, National Research Foundation of Korea
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon